More than 100 mothers and advocates affected by a type of rare disease gathered outside the Food and Drug Administration (FDA) on Wednesday to stage a funeral to "mourn the futures" of their children, following the agency's rejections of various rare disease treatments.

This action marks first drug approved for pediatric patients with acquired thrombotic thrombocytopenic purpura The U.